AU1591699A - Statin-matrix metalloproteinase inhibitor combinations - Google Patents

Statin-matrix metalloproteinase inhibitor combinations Download PDF

Info

Publication number
AU1591699A
AU1591699A AU15916/99A AU1591699A AU1591699A AU 1591699 A AU1591699 A AU 1591699A AU 15916/99 A AU15916/99 A AU 15916/99A AU 1591699 A AU1591699 A AU 1591699A AU 1591699 A AU1591699 A AU 1591699A
Authority
AU
Australia
Prior art keywords
acid
methyl
phenyl
ethyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15916/99A
Other languages
English (en)
Inventor
Roger Schofield Newton
Bruce David Roth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU1591699A publication Critical patent/AU1591699A/en
Priority to AU2003248291A priority Critical patent/AU2003248291A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU15916/99A 1998-03-17 1998-11-20 Statin-matrix metalloproteinase inhibitor combinations Abandoned AU1591699A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003248291A AU2003248291A1 (en) 1998-03-17 2003-09-12 Statin-matrix metalloproteinase inhibitor combinations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17
US60078265 1998-03-17
PCT/US1998/024681 WO1999047138A1 (en) 1998-03-17 1998-11-20 Statin-matrix metalloproteinase inhibitor combinations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003248291A Division AU2003248291A1 (en) 1998-03-17 2003-09-12 Statin-matrix metalloproteinase inhibitor combinations

Publications (1)

Publication Number Publication Date
AU1591699A true AU1591699A (en) 1999-10-11

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15916/99A Abandoned AU1591699A (en) 1998-03-17 1998-11-20 Statin-matrix metalloproteinase inhibitor combinations

Country Status (18)

Country Link
EP (1) EP1063991A1 (ja)
JP (1) JP2002506818A (ja)
KR (1) KR20010041916A (ja)
AR (1) AR018113A1 (ja)
AU (1) AU1591699A (ja)
BR (1) BR9815745A (ja)
CA (1) CA2309588A1 (ja)
CO (1) CO5070670A1 (ja)
GT (1) GT199900039A (ja)
HN (1) HN1999000029A (ja)
MY (1) MY140504A (ja)
NZ (1) NZ505994A (ja)
PA (1) PA8469001A1 (ja)
PE (1) PE20000348A1 (ja)
SV (1) SV1999000026A (ja)
UY (1) UY25436A1 (ja)
WO (1) WO1999047138A1 (ja)
ZA (1) ZA992106B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
EP1827448A1 (en) 2004-12-15 2007-09-05 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
US20110182851A1 (en) * 2008-07-11 2011-07-28 Jan Nilsson Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA000514B1 (ru) * 1995-11-02 1999-10-28 Варнер-Ламберт Компани Способ нормализации липопротеидного профиля плазмы крови у млекопитающего и фармацевтическая композиция для его осуществления
EA001561B1 (ru) * 1996-05-17 2001-04-23 Варнер-Ламберт Компани Бифенилсульфонамидные ингибиторы матричных металлопротеиназ
NZ334897A (en) * 1996-12-09 2001-02-23 Warner Lambert Co Medicaments for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
PA8469001A1 (es) 2002-09-17
HN1999000029A (es) 1999-09-29
SV1999000026A (es) 2000-01-18
KR20010041916A (ko) 2001-05-25
ZA992106B (en) 1999-09-30
UY25436A1 (es) 2001-10-25
GT199900039A (es) 2000-09-06
CA2309588A1 (en) 1999-09-23
WO1999047138A1 (en) 1999-09-23
PE20000348A1 (es) 2000-05-22
CO5070670A1 (es) 2001-08-28
MY140504A (en) 2009-12-31
JP2002506818A (ja) 2002-03-05
AR018113A1 (es) 2001-10-31
NZ505994A (en) 2003-10-31
EP1063991A1 (en) 2001-01-03
BR9815745A (pt) 2000-11-14

Similar Documents

Publication Publication Date Title
AU741768B2 (en) Method for treating and preventing heart failure and ventricular dilatation
AU751701B2 (en) Ace inhibitor-MMP inhibitor combinations
US6340709B1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
AU4701799A (en) Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions
US20020049237A1 (en) Statin-MMP inhibitor combinations
AU1591699A (en) Statin-matrix metalloproteinase inhibitor combinations
US20050020607A1 (en) Statin-MMP inhibitor combinations
AU2003248291A1 (en) Statin-matrix metalloproteinase inhibitor combinations
MXPA00005034A (en) Statin-matrix metalloproteinase inhibitor combinations
MXPA00003736A (en) Ace inhibitor-mmp inhibitor combinations
EP1366765A1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
MXPA01000780A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
MXPA99002254A (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted